BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Providing Reliable, Consistent Dose Administration and Monitoring Devices

RYAH Group (CSE: RYAH), a connected device and big data and technology company, offers a suite of precision intake control and management devices that provide a practical way to execute volume control guidelines safely. In a company blog post, discussed in a recent article, RYAH noted that a global task force had created three separate dosing protocols: routine administration, conservative administration and rapid administration, with each designed to ease a patient treating chronic pain into medical cannabis and treatment with THC if needed. Such dosing guidelines are just half of the equation. The other half is the delivery mechanism, as patients need a reliable way to receive consistent and measurable doses to adhere to their treatment protocols. Physicians also need a way to monitor patent titration and dose size. This is where RYAH Group’s devices come in. “The RYAH Smart Patch, Inhaler and Pen enable patients and physicians to control their medicine, the specific administration volume and the protocol behind the treatment. In addition, detailed analytics provided by these RYAH devices help determine which intake volumes are working and what needs adjusting, and a patient’s progress in their treatment.”

To view the full article, visit https://ibn.fm/xwLNW

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information, visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH 

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork